IRMD
IRADIMED CORP
NASDAQ · Healthcare · Medical - Devices · US
$88.55
+9.18%Year over year
Reported trailing growth
- Revenue
- +11.0%
- EBITDA
- +14.2%
- EBIT
- +16.1%
- EPS
- +13.2%
- Free cash flow
- +81.5%
- Operating cash flow
- +8.5%
Forward estimates
Based on analyst estimates
- Revenue
- +13.6%
- EBITDA
- +25.7%
- EPS
- +26.7%
Three-year CAGR
- Revenue
- +16.3%
- EBITDA
- +20.6%
- EBIT
- +18.7%
- Net income
- +20.6%
- EPS
- +20.2%
- Free cash flow
- +28.1%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Sep 1, 2026